Cedars Sinai Uses AlloSure in Tocilizumab Trial
ABMR is recognized as the leading cause of late kidney transplant failure. Long-term graft survival has not improved, primarily due to late diagnosis and lack of effective therapeutic options. Cedars-Sinai is testing an Interleukin-6 blockade, tocilizumab, as a treatment for patients with ABMR. They will use AlloSure to optimize the therapy regime.
“This study will give us the opportunity to evaluate a novel biomarker with AlloSure in an effort to optimize management of kidney transplant recipients being treated for chronic ABMR,” said Dr.
“We are glad to sponsor this investigator initiated trial at Cedars Sinai to help evaluate the efficacy of this new biologics-based drug therapy in a patient group that needs better solutions,” said
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements, including expectations regarding the Company’s fiscal 2019 revenue, achievement of our financial and operational goals and our prospects. These forward-looking statements are based upon information that is currently available to
Chief Commercial Officer
Integrated Corporate Relations, Inc.
Source: CareDx, Inc.